Lipo-C Injection vs Semaglutide
A side-by-side research comparison of Lipo-C Injection and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Lipo-C Injection | Semaglutide |
|---|---|---|
| Full name | Lipotropic MIC + B12 Injection | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Compounded medication | FDA Approved |
| Mechanism | Methionine provides sulfur for detoxification, inositol supports fat transport from liver, choline emulsifies cholesterol and fat, B12 boosts cellular energy metabolism and red blood cell production. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | Combination compound | 4,114 Da |
| Half-life | Variable by component | 7 days (168 hours) |
| Bioavailability | ~100% IM injection | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 1 mL | 0.25 mg → titrate up to 2.4 mg |
| Frequency | 1-2x per week | Once weekly |
| Route | Intramuscular or subcutaneous injection | Subcutaneous injection |
Lipo-C Injection reported benefits
- Enhanced fat metabolism
- Liver support
- Increased energy
- B12 optimization
- Complements weight loss protocols
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.